Clinical  ||| S:0 E:9 ||| JJ
guideline  ||| S:9 E:19 ||| NN
recommendations  ||| S:19 E:35 ||| NNS
for  ||| S:35 E:39 ||| IN
antipsychotic  ||| S:39 E:53 ||| JJ
long-acting  ||| S:53 E:65 ||| JJ
injections  ||| S:65 E:76 ||| NNS
Long-acting  ||| S:76 E:88 ||| JJ
injections  ||| S:88 E:99 ||| NNS
( ||| S:99 E:100 ||| -LRB-
LAIs ||| S:100 E:104 ||| NNP
)  ||| S:104 E:106 ||| -RRB-
of  ||| S:106 E:109 ||| IN
antipsychotic  ||| S:109 E:123 ||| JJ
drugs  ||| S:123 E:129 ||| NNS
were  ||| S:129 E:134 ||| VBD
developed  ||| S:134 E:144 ||| VBN
over  ||| S:144 E:149 ||| IN
40  ||| S:149 E:152 ||| CD
years  ||| S:152 E:158 ||| NNS
ago  ||| S:158 E:162 ||| RB
in  ||| S:162 E:165 ||| IN
an  ||| S:165 E:168 ||| DT
attempt  ||| S:168 E:176 ||| NN
to  ||| S:176 E:179 ||| TO
improve  ||| S:179 E:187 ||| VB
the  ||| S:187 E:191 ||| DT
long-term  ||| S:191 E:201 ||| JJ
treatment  ||| S:201 E:211 ||| NN
of  ||| S:211 E:214 ||| IN
schizophrenia ||| S:214 E:227 ||| NN
.  ||| S:227 E:229 ||| .
To  ||| S:229 E:232 ||| TO
review  ||| S:232 E:239 ||| VB
existing  ||| S:239 E:248 ||| VBG
guidelines  ||| S:248 E:259 ||| NNS
concerning  ||| S:259 E:270 ||| VBG
antipsychotic  ||| S:270 E:284 ||| NNS
use  ||| S:284 E:288 ||| VBP
generally ||| S:288 E:297 ||| RB
,  ||| S:297 E:299 ||| ,
and  ||| S:299 E:303 ||| CC
LAIs  ||| S:303 E:308 ||| JJ
in  ||| S:308 E:311 ||| IN
particular ||| S:311 E:321 ||| JJ
,  ||| S:321 E:323 ||| ,
and  ||| S:323 E:327 ||| CC
how  ||| S:327 E:331 ||| WRB
patients  ||| S:331 E:340 ||| NNS
might  ||| S:340 E:346 ||| MD
be  ||| S:346 E:349 ||| VB
identified  ||| S:349 E:360 ||| VBN
as  ||| S:360 E:363 ||| IN
potential  ||| S:363 E:373 ||| JJ
candidates  ||| S:373 E:384 ||| NNS
for  ||| S:384 E:388 ||| IN
LAI  ||| S:388 E:392 ||| NNP
treatment ||| S:392 E:401 ||| NN
.  ||| S:401 E:403 ||| .
Literature  ||| S:403 E:414 ||| NN
review ||| S:414 E:420 ||| NN
.  ||| S:420 E:422 ||| .
Currently  ||| S:422 E:432 ||| RB
several  ||| S:432 E:440 ||| JJ
first-generation  ||| S:440 E:457 ||| JJ
and  ||| S:457 E:461 ||| CC
one  ||| S:461 E:465 ||| CD
second-generation  ||| S:465 E:483 ||| JJ
antipsychotic  ||| S:483 E:497 ||| JJ
LAIs  ||| S:497 E:502 ||| NNS
are  ||| S:502 E:506 ||| VBP
available ||| S:506 E:515 ||| JJ
,  ||| S:515 E:517 ||| ,
with  ||| S:517 E:522 ||| IN
others  ||| S:522 E:529 ||| NNS
under  ||| S:529 E:535 ||| IN
development ||| S:535 E:546 ||| NN
.  ||| S:546 E:548 ||| .
Although  ||| S:548 E:557 ||| IN
the  ||| S:557 E:561 ||| DT
use  ||| S:561 E:565 ||| NN
of  ||| S:565 E:568 ||| IN
LAIs  ||| S:568 E:573 ||| NNP
is  ||| S:573 E:576 ||| VBZ
widespread  ||| S:576 E:587 ||| JJ
around  ||| S:587 E:594 ||| IN
the  ||| S:594 E:598 ||| DT
world ||| S:598 E:603 ||| NN
,  ||| S:603 E:605 ||| ,
patterns  ||| S:605 E:614 ||| NNS
of  ||| S:614 E:617 ||| IN
use  ||| S:617 E:621 ||| NN
vary  ||| S:621 E:626 ||| VBP
widely ||| S:626 E:632 ||| RB
.  ||| S:632 E:634 ||| .
Important  ||| S:634 E:644 ||| JJ
considerations  ||| S:644 E:659 ||| NNS
regarding  ||| S:659 E:669 ||| VBG
the  ||| S:669 E:673 ||| DT
use  ||| S:673 E:677 ||| NN
of  ||| S:677 E:680 ||| IN
LAIs  ||| S:680 E:685 ||| NNS
include  ||| S:685 E:693 ||| VBP
the  ||| S:693 E:697 ||| DT
indications  ||| S:697 E:709 ||| NNS
for  ||| S:709 E:713 ||| IN
long-term  ||| S:713 E:723 ||| JJ
pharmacotherapy  ||| S:723 E:739 ||| NN
in  ||| S:739 E:742 ||| IN
schizophrenia  ||| S:742 E:756 ||| NN
in  ||| S:756 E:759 ||| IN
general ||| S:759 E:766 ||| JJ
,  ||| S:766 E:768 ||| ,
the  ||| S:768 E:772 ||| DT
indications  ||| S:772 E:784 ||| NNS
for  ||| S:784 E:788 ||| IN
LAIs ||| S:788 E:792 ||| NNP
,  ||| S:792 E:794 ||| ,
the  ||| S:794 E:798 ||| DT
risks  ||| S:798 E:804 ||| NNS
associated  ||| S:804 E:815 ||| VBN
with  ||| S:815 E:820 ||| IN
LAIs ||| S:820 E:824 ||| NNP
,  ||| S:824 E:826 ||| ,
the  ||| S:826 E:830 ||| DT
need  ||| S:830 E:835 ||| NN
to  ||| S:835 E:838 ||| TO
update  ||| S:838 E:845 ||| VB
guidelines  ||| S:845 E:856 ||| NNS
and  ||| S:856 E:860 ||| CC
the  ||| S:860 E:864 ||| DT
issue  ||| S:864 E:870 ||| NN
of  ||| S:870 E:873 ||| IN
cost ||| S:873 E:877 ||| NN
.  ||| S:877 E:879 ||| .
The  ||| S:879 E:883 ||| DT
use  ||| S:883 E:887 ||| NN
of  ||| S:887 E:890 ||| IN
these  ||| S:890 E:896 ||| DT
injections  ||| S:896 E:907 ||| NN
in  ||| S:907 E:910 ||| IN
first-episode  ||| S:910 E:924 ||| JJ
psychosis  ||| S:924 E:934 ||| NN
and  ||| S:934 E:938 ||| CC
treatment-refractory  ||| S:938 E:959 ||| JJ
schizophrenia  ||| S:959 E:973 ||| NN
is  ||| S:973 E:976 ||| VBZ
not  ||| S:976 E:980 ||| RB
currently  ||| S:980 E:990 ||| RB
a  ||| S:990 E:992 ||| DT
focus  ||| S:992 E:998 ||| NN
of  ||| S:998 E:1001 ||| IN
recommendations ||| S:1001 E:1016 ||| NNS
,  ||| S:1016 E:1018 ||| ,
but  ||| S:1018 E:1022 ||| CC
should  ||| S:1022 E:1029 ||| MD
be  ||| S:1029 E:1032 ||| VB
considered ||| S:1032 E:1042 ||| VBN
.  ||| S:1042 E:1044 ||| .
Long-acting  ||| S:1044 E:1056 ||| JJ
injections  ||| S:1056 E:1067 ||| NNS
remain  ||| S:1067 E:1074 ||| VBP
an  ||| S:1074 E:1077 ||| DT
underutilised  ||| S:1077 E:1091 ||| JJ
option  ||| S:1091 E:1098 ||| NN
in  ||| S:1098 E:1101 ||| IN
many  ||| S:1101 E:1106 ||| JJ
countries  ||| S:1106 E:1116 ||| NNS
despite  ||| S:1116 E:1124 ||| IN
frequent  ||| S:1124 E:1133 ||| JJ
non-adherence  ||| S:1133 E:1147 ||| NN
with  ||| S:1147 E:1152 ||| IN
oral  ||| S:1152 E:1157 ||| JJ
medication  ||| S:1157 E:1168 ||| NN
and  ||| S:1168 E:1172 ||| CC
subsequent  ||| S:1172 E:1183 ||| JJ
relapse ||| S:1183 E:1190 ||| NN
.  ||| S:1190 E:1192 ||| .
